Ultra fast-acting insulin analogue - Adocia

Drug Profile

Ultra fast-acting insulin analogue - Adocia

Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BioChaperone Lispro; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Lispro U100; BioChaperone® Lispro U200; BioChaperone® Ultra Fast Lispro

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adocia
  • Developer Adocia; Tonghua Dongbao Pharmaceutical
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 18 Jul 2018 Clinical trials in Type-1 diabetes mellitus in China (SC)
  • 18 Jul 2018 Clinical trials in Type-2 diabetes mellitus in China (SC)
  • 18 Jul 2018 Tonghua Dongbao plans phase III development in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top